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Abstract 
Purpose/Background 
Clozapine is associated with haematological abnormalities, notably neutropenia, which may progress 
to agranulocytosis. Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage 
colony-stimulating factor (GM-CSF) have been used to reduce the frequency and duration of 
5	  
	  
clozapine-associated neutropenia. This review aims to explore the use, efficacy, and tolerability of 
these cytokines in the treatment of clozapine-associated agranulocytosis.  
Methods/Procedures 
We conducted a systematic review of published interventional, observational studies, case series, and 
case reports where G-CSF/GM-CSF was used to treat clozapine-associated agranulocytosis. 
Findings/Results 
We identified 29 reports (40 patients). The median duration of neutrophil recovery time after stopping 
clozapine and starting cytokine treatment was 7.0 days (range 2-13 days) for those with 
agranulocytosis (absolute neutrophil count (ANC) < 0.5 x 109 cells/L). Ninety-four percent (n=29) 
had no serious adverse reactions, and no deaths occurred.  
Implications/Conclusions 
Our findings indicate that G-CSF/GM-CSF use is well tolerated, and suggest that GCSF can 
sometimes be safely used to reduce the duration of neutropenia associated with clozapine use. 
However, the interpretation of this outcome is difficult given the likely publication bias for positive 
outcomes in case reports. 
Keywords: granulocyte colony stimulating factors; G-CSF; GM-CSF; treatment-resistant; 
schizophrenia; clozapine 
Introduction 
Clozapine remains the gold-standard treatment for treatment resistant schizophrenia. (1, 2) However, 
the use of clozapine is restricted in part due to its risk of inducing neutropenia, which may progress to 
agranulocytosis unless clozapine is promptly withdrawn. The cumulative incidence of clozapine-
induced neutropenia (defined as an absolute neutrophil count (ANC) < 1.5 x 109 cells/L) is 2.7 % over 
the first year of use. (3) The cumulative incidence of clozapine-induced agranulocytosis (CIA) 
(defined as an ANC < 0.5 x 109cells/L) is 0.8 % at 1 year and 0.91 % at 18 months, (4) with the 
highest incidence at 6-18 weeks after commencing clozapine. (5) Clozapine use is accompanied by 
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the requirement for regular full blood count (FBC) monitoring in many countries, and if the total 
leucocyte and/or neutrophil counts indicate the development of neutropenia or agranulocytosis, clear 
criteria exist for drug withdrawal. The strategy combined with modern treatment options has largely 
prevented deaths from this serious adverse reaction: with the mortality rate from CIA is estimated to 
be 0.01–0.03 % (case-fatality rate 2.2–4.2 %). (6) 
In most countries, (7) when neutropenia occurs during clozapine treatment, clozapine must be 
discontinued. Depending on a patient’s clinical state, management may be supportive with daily 
monitoring of the full blood count until the neutrophil count normalizes, or may involve the 
administration of antibiotics if there is a febrile neutropenia.  Granulocyte colony-stimulating factors 
(G-CSFs), and granulocyte-macrophage colony-stimulating factors (GM-CSFs) have been used to 
treat clozapine associated neutropenia. Both agents are typically administered during chemotherapy in 
order to reduce the incidence or the duration of neutropenia. (8, 9)  They stimulate proliferation and 
differentiation of committed myeloid progenitor cells in the bone marrow.(10) G-CSF has supplanted 
the use of GM-CSF in recent years. While both agents stimulate granulocyte production, G-CSF also 
shortens the maturation phase from progenitor cells to the neutrophil granulocyte, further increasing 
the peripheral neutrophil count.(11)  Filgrastim and lenograstim are the most commonly used G-CSFs, 
and are administered by subcutaneous injection. They both have short plasma half-lives (lenograstim 
t1/2 approximately 3 hours(12) ; filgrastim t 1/2 approximately 3.5 hours, (13) and are  excreted renally. 
Both G-CSF and GM-CSF have been used increasingly to treat clozapine induced 
agranulocytosis.(14, 15) However, knowledge of their use in clozapine patients is limited. Their use in 
the treatment of agranulocytosis induced by non-chemotherapeutic agents has been reviewed, (16) 
however no similar review of their use for clozapine associated agranulocytosis has been performed.  
Aims 
We aimed to review the literature to investigate the effect of G-CSFs and GM-CSFs in reducing the 
duration of clozapine associated agranulocytosis; to describe the doses of G-CSF used and; to review 
the tolerability of these agents.  
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Methods 
We performed a literature search to identify peer-reviewed interventional and observational studies, 
case series and case reports, up until August 2016, investigating or describing G-CSF or GM-CSF as a 
treatment for clozapine associated agranulocytosis. This systematic review was conducted in 
accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 
standard. (17)  
Inclusion criteria 
Studies and case reports of patients (no age restrictions) who were treated with G-CSF or GM-CSF 
for clozapine associated agranulocytosis (with an ANC < 0.5 x109 cells/L), including patients who 
developed a neutropenia during rechallenge.  For those cases of neutropenia with an ANC < 0.1 x109 
cells/L, we described it as severe agranulocytosis, to distinguish a condition where an individual is at 
an increased risk of morbidity and mortality from infections, and to make it distinct from 
agranulocytosis (ANC< 0.5 x109 cells/L).(18) 
Exclusion criteria 
Studies were excluded if:  G-CSF or GM-CSF was used to support the maintenance of clozapine 
treatment during chemotherapy; if there was insufficient laboratory data to permit further evaluation 
of the report; they described a neutropenia with an absolute neutrophil count (ANC) > 0.5 x109 cells/L 
or; with an ANC of >1.5x109 cells/L.  
Information sources and searches 
Two independent reviewers (JL and SM) performed an electronic search using PubMed, Medline, 
Scopus, EMBASE and Google Scholar from inception until August 2016. The following search terms 
were used, alone and in combination: Granulocyte Colony-Stimulating Factor OR granulocyte-
macrophage colony-stimulating OR GCSF OR G-CSF  OR GMCSF OR GM-CSF AND clozapine  
OR  clozaril  OR  denzapine  OR  zaponex OR leponex. In addition, the reference lists of the retrieved 
articles and relevant review articles were examined for further reports 
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Study selection and exclusion 
All extracted reports were examined independently by two authors (JL and SM) and a list of full text 
articles established.  Authors were contacted for clarification where necessary. There were 29 
qualifying reports, 7 of which were case series and 22 case reports. In total 40 patients were identified 
who received G-CSF or GM-CSF as treatment for clozapine associated agranulocytosis.  
Primary and secondary outcomes 
The primary outcome was the time for neutrophil recovery after starting G-CSF (as defined by 
recovery either to within the normal range of a local laboratory, or a neutrophil count > 2.0 x109 
cells/L). For secondary outcomes, we examined for associations between neutrophil recovery time 
and the nadir neutrophil count (specifically the occurrence of agranulocytosis), the type of G-CSF or 
GM-CSF used, and the cumulative dose of G-CSF or GM-CSF used. The tolerability of G-CSF and 
GM-CSF was assessed, and outcomes including mortality due to complications secondary to 
neutropenia or agranulocytosis were recorded. The incidence of rebound leukocytosis (as defined by 
each study or a WCC>10.0 X109/L) was recorded and associations between leukocytosis and dose and 
duration of G-CSF or GM-CSF use were assessed.  
Data extraction 
The following information was extracted where possible: demographic and clinical characteristics of 
patients, mean clozapine dosage (mg/d) at the time of the neutropenic event, and duration of clozapine 
therapy prior to onset of neutropenia , plasma clozapine concentrations reported pre neutropenia, nadir 
neutrophil count, duration of neutropenia prior to the use of G-CSF or GM-CSF, duration of 
neutropenia following administration of G-CSF or GM-CSF and duration of G-CSF or GM-CSF use 
and total duration of neutropenia; antibiotic use; adverse effects associated with G-CSF or GM-CSF 
and; rebound leukocytosis associated with G-CSF or GM-CSF use.  
Results 
Study selection, study and participant characteristics 
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The study selection process, search results, and reasons for exclusion are given in figure 1. 
The initial search yielded 766 references. After checking titles and abstracts, 57 full texts were 
screened and 29 of these (40 patients) were included for data extraction. (15, 19-46) All were case 
series or reports; no interventional or observational studies were identified. 
Acute treatment with G-CSF for clozapine-associated neutropenia or agranulocytosis 
The demographic and clinical characteristics of the group are shown in table 1. Twenty-seven (67.5% 
of total population) had a severe agranulocytosis, with an ANC <0.1 x109 cells/L. Nine patients 
(39.0% of those in whom a clozapine first treatment or rechallenge status was reported) had 
developed a further neutropenia during clozapine rechallenge. There was insufficient data in relation 
to plasma clozapine concentrations to report in this review. 
Clozapine was discontinued in all patients at onset of neutropenia. Antibiotics were administered to 
21 patients. Bone marrow aspiration was performed in 11 patients (55.0% of those cases in which 
bone narrow aspiration was reported to be performed or not).  Twenty-three patients (97.5% of those 
in whom G-CSF type was specified) were treated with filgrastim, while a single patient was treated 
with sarcograstim.  The outcome characteristics of G-CSF or GM-CSF use are described in table 2. 
There were no deaths recorded.  
The median time to neutrophil recovery was 7.0 days for all patients. For those with an ANC of 0.1-
0.5 x109 cells/L, the median duration of neutrophil recovery time was 6.0 days.  The mean total dose 
of filgrastim used was 399 ± 198 mcg (dose range 125-900 mcg). There was no significant difference 
in mean time to neutrophil recovery between those treated with a lower daily dose of filgrastim (i.e. 5 
mcg/kg/day or less) (n=4) (7.0±1.4 days) compared to those treated with 10mcg/kg/day (n=3) (6.3 
±3.5 days) (t=0.352, p=0.739). The dose of filgrastrim used was not significantly correlated with the 
time to neutrophil recovery (r=0.554, p=0.050) following its administration controlling for concurrent 
antibiotic use, baseline neutrophil count and duration of neutropenia prior to G-CSF administration.   
Adverse events 
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No adverse reactions to G-CSF or GM-CSF were reported in 29 cases (93.5% of those in whom 
reports referred to the presence or absence of adverse events). One female patient developed a 
thrombocytosis with clinical signs of deep vein thrombosis (DVT)(43) after seven days treatment with 
G-CSF at a dose of 300 mcg/day(with a maximum platelet count of 800 x 109/L). The platelet count 
normalised seven days after the discontinuation of G-CSF, with no further evidence of 
thrombosis.(43) Another patient,(42)  a 30 year old man, developed a right middle cerebral artery 
infarct, after three days of treatment with GM-CSF 300 mcg/day (ANC= 0.1 x109 cells/L).(42) The 
activated partial thromboplastin time was prolonged at 39 s (normal range < 36 s), with a normal 
prothrombin time. There were no reports of bony or musculoskeletal pain, fever, headache, arthritic 
flare ups or splenomegaly. No deaths occurred. 
Ten (46% of those cases in whom WCC were reported following G-CSF or GM-CSF use) of the 
patients had evidence of a rebound leucocytosis. For 11 of these cases, the average time to 
normalisation of the leucocytosis (as defined by each study or a WCC< 10.0 X109/L) was 11.6 (15.5) 
days (range 0-50 days). No adverse events were reported in association with these events. The average 
dose of filgrastim used was not significantly associated with the occurrence of leucocytosis (mean 
dose 540.0 ±270.6mcg in those with a leucocytosis (n=7) compared to a mean dose of 411.4 ±144.6 
mcg in those with no leucocytosis (n=7) (t=1.109, p=0.289)). Further, the average duration of G-CSF 
use was not significantly associated with the occurrence of leucocytosis (mean of 7.9 ±3.0 days in 
those with leucocytosis compared to a mean of 7.3 ±3.1 days in those with no leucocytosis (t=0.434, 
p=0.669).  
Discussion 
In this, the first systematic review of the use of G-CSF for the treatment of clozapine associated 
neutropenia and agranulocytosis, we identify that G-CSF treatment may be beneficial for patients in 
aiding with neutrophil recovery following the discontinuation of clozapine.     
GCSF for acute treatment of clozapine associated agranulocytosis and neutropenia 
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The median time to neutrophil recovery in agranulocytosis following administration of G-CSF was 
7.0 days. This is shorter than the 12 day median duration of neutropenia recovery associated with 
clozapine use without treatment with GCSF identified in a systematic review of case reports of drug 
induced agranulocytosis (defined by ANC<0.5x109) (for case reports published since 1990).(16) 
Thus, the use of G-CSF in clozapine associated neutropenia may shorten the duration of neutropenia 
by half, and is notably less than the previously reported duration of clozapine associated 
agranulocytosis (defined by ANC<0.5x109)  not treated with G-CSF of 14-21 days.(15) Given that the 
duration of agranulocytosis is an important prognostic factor in drug induced agranulocytosis,(47) our 
finding of a duration of neutrophil recovery with G-CSF use of 7 days,  is clinically significant and 
suggests that G-CSF use should be more prominently considered for those with clozapine associated 
agranulocytosis.  
For those with severe agranulocytosis ( ANC <0.1x109 cells/L), the mean time to neutrophil recovery 
following administration of G-CSF was 7.7 ± 3.1 days,  and is comparable to the recovery time 
identified in a systematic review of case reports in which G-CSF was used to treat non-cytotoxic drug 
induced agranulocytosis (all drugs and not just clozapine) (defined as an ANC<0.1 x109 cells/L) 
(mean=7.7±5.1 days (n=100 cases).(16) Our findings for an enhanced neutrophil recovery time with 
the use of G-CSF in severe agranulocytosis, mirrors those for its use in agranulocytosis and severe 
agranulocytosis caused by other non-chemotherapeutic drugs, and supporting the use of G-CSF for 
this clozapine associated agranulocytosis.  
No deaths were reported in those treated with G-CSF. G-CSF or GM-CSF was well tolerated in all but 
two cases, (42, 43) with no severe adverse events identified in the others. In one case, GM-CSF was 
associated with arterial thrombosis. This case was associated with a prolonged APTT, which may be 
seen with antiphospholipid syndrome-though the patient was negative for anticardiolipin antibodies. 
A previous meta-analysis suggested that the use of GM-CSF compared to G-CSF was associated with 
an increased thrombotic risk, (48) though we were unable to investigate this due to the low numbers 
treated with GM-CSF. In the other case with an adverse reaction, a female patient treated with G-CSF 
developed a DVT. (43) 
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Forty-six percent of patients had a rebound leucocytosis, following the administration of G-CSF for 
the treatment of clozapine associated neutropenia, which lasted for an average duration of 12 days. 
This was not associated with the use of a higher mean dose of filgrastim or with a longer duration of 
G-CSF use. No overt clinical events were associated with this, including no reports of thrombotic 
events. However, given the high rate of occurrence of rebound leucocytosis, we recommend that 
clinicians continue to monitor white cell and platelet counts until normalisation occurs and monitor 
patients for clinical evidence of venous thrombosis; and for arterial thrombosis, monitoring for 
cardiac symptoms such as chest pain, neurological symptoms such as weakness, speech disturbance, 
confusion, and pain in limbs, and for pulmonary oedema, and hyperviscosity syndrome (e.g. 
headache, blurred vision). 
Limitations 
The primary limitation is the possibility of publication bias. Most patients with clozapine associated 
neutropenia/agranulocytosis are not reported in the literature, and it is likely that G-CSF is more 
widely used for the treatment of these episodes than is indicated here. It is possible that a bias towards 
reporting cases in which there is a favourable outcome after treatment with G-CSF may have 
occurred.  It is also possible that cases in which adverse reactions or deaths have occurred are more 
likely to have been reported. There is no agreed method to assess the effect of publication bias in case 
reports.  Further caution is required when interpreting the results, as data is lacking on numerous 
confounding factors which may have influenced when and why the decision was made to intervene 
with cytokine treatment, factors that are treated differently from one case to the next. Finally, as no 
comparative or observational studies were identified, we are unable to confirm that the duration of 
time to recovery is shortened, or that morbidity/mortality are reduced.  The possibility remains that no 
treatment -- discontinuing clozapine and allowing recovery to take its course -- may be the most 
beneficial approach.   
Conclusions 
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Our review demonstrates benefits for the use of G-CSF for patients with clozapine associated 
neutropenia/agranulocytosis. A prospective placebo controlled trial to establish the efficacy of G-CSF 
in clozapine associated neutropenia/agranulocytosis would be the gold standard study. The rarity of 
clozapine-induced neutropenia may make such a study impractical outside highly specialised centres. 
As such, observational and retrospective studies to establish the efficacy of G-CSF in clozapine 
associated agranulocytosis would be the first choice for future research. Until such studies are 
conducted, this review of the available evidence suggests that G-CSF may be a valuable tool in the 
treatment of clozapine associated neutropenia. However, the possibility of publication bias towards 
favourable outcomes cannot be ruled out.  
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Table	  1.	  Characteristics	  of	  Patients	  with	  clozapine	  associated	  agranulocytosis	  (n=40)	  
	  
	   	  
Gender	  n	  (	  %)	  
Male	  
Female	  
Not	  reported	  
	  
21	  (52%)	  
15	  (38%)	  
4	  	  	  (10%)	  
Mean	  age	  ±	  SD	  (range)	   45.2	  ±14.4	  	  	  (13-­‐85)	  
Clozapine	  rechallenge	  
Yes	  
No	  
Not	  reported	  
	  
9	  (22.5%)	  
14	  (35%)	  
17	  (42.5%)	  
Mean	  clozapine	  dose	  at	  time	  of	  neutropenia	  (range)	  mg	   393.1	  ±18.6	  (25.0-­‐900.0)	  
Mean	  duration	  of	  clozapine	  use	  prior	  to	  neutropenia	  
onset±	  SD	  (median;	  range)	  days	  
195.2±336.0	  (56;	  27-­‐
1620)	  
16	  
	  
Mean	  neutrophil	  count	  nadir	  ±	  SD	  (range)	  x109	  cells/L	  	   0.11	  ±0.14	  (0-­‐0.5)	  
Severe	  agranulocytosis	  (ANC	  <1.5	  x109	  cells/L)	  
Yes	  
No	  
	  
27	  (67.5%)	  
13	  (32.5%)	  
Antibiotics	  used	  
Yes	  
No	  
Not	  reported	  
	  
21	  (53%)	  
11	  (27%)	  
	  	  8	  (20%)	  
G-­‐CSF	  use	  
GM-­‐CSF	  use	  
Both	  G-­‐CSF	  and	  GM-­‐CSF	  use	  
36	  (90%)	  
3	  (7.5%)	  
1	  (2.5%)	  
Adverse	  events	  
Yes	  
No	  
Not	  reported	  
	  
2	  	  	  (5.0%)	  
29	  (72.5%)	  
9	  (	  22.5%)	  
Rebound	  leucocytosis	  
Yes	  
No	  	  
Not	  reported	  
	  
10	  (25%)	  
12	  (30%)	  
18	  (45%)	  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table	  2	  Outcome	  and	  response	  to	  G-­‐CSF	  and	  GM-­‐CSF	  in	  clozapine	  associated	  agranulocytosis	  
(n=40)	  
	   All	  patients	   Agranulocytosis	  (ANC	  	  
0.1-­‐0.5	  X109	  cells/L)	  	  
Severe	  agranulocytosis	  
(ANC	  <0.1X109	  cells/L)	  
T	  test;	  p	  
value	  
Recovery	   40	   13	   27	   	  
Mean	  duration	  of	  neutropenia	  
prior	  to	  use	  of	  G-­‐CSF	  (±SD)	  
(median;	  range)	  days	  
4.1	  ±4.4	  (2.5;0-­‐
17)	  
3.5±4.6	   4.3±4.3	   0.472;	  
0.641	  
Mean	  duration	  of	  neutrophil	  
recovery	  after	  G-­‐CSF	  initiation	  
7.2±	  3.0	  (7.0;	  2-­‐ 5.9±2.6	   7.7±3.1	   1.660;	  
17	  
	  
(±SD)	  (median;	  range)	  days	   13)	   0.107	  
Mean	  total	  duration	  of	  
neutropenia	  (pre	  and	  post	  G-­‐CSF)	  
(±SD)	  (median;	  range)	  days	  
11.6±	  4.7	  (11;3-­‐
26)	  
10.4±4.6	   12.2±4.7	   1.058;	  
0.298	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records	  identified	  through	  
database	  searching	  	  
(n	  =766)	  
Records	  after	  duplicates	  removed	  	  
(n	  =683)	  
Studies	  included	  from	  
database	  search	  (n=52)	  
(n	  =	  55	  	  )	  
Articles	  excluded	  at	  
title/abstract	  level	  (n=631)	  
(n	  =	  12	  	  )	  
Fig.1.	  Flow	  diagram	  of	  article	  search	  
and	  review	  process	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Full-­‐text	  articles	  assessed	  
for	  eligibility	  	  
(n	  =	  57)	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  Exclusion	  (n	  =	  28):	  
• Systematic	  review	  (n=3)	  
• Inappropriate	  study	  
population	  (n=24)	  
• Incomplete	  data	  
information	  (n=1)	  
	  
Studies	  included	  in	  review	  	  
(n	  =29)	  
Potentially	  eligible	  articles	  identified	  via	  
hand	  search	  (N=5)	  
(n	  =	  12	  	  )	  
